Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging.

Shin Yaogawa,Shinji Kariya,Ryo Akima,Masahide Onogawa,Akira Tsuzuki,Kenji Itoh,Mitsuhiko Miyamura,Hiroaki Yasunami,Kazuo Morio,Yasuhiro Ogawa,Shiho Morita-Tokuhiro,Munenobu Nogami,Akihito Nishioka

doi:10.3390/cancers8010001

Shin Yaogawa, Shinji Kariya + Show 11 more

Open Access

https://doi.org/10.3390/cancers8010001

Copy DOI

Journal: Cancers	Publication Date: Dec 22, 2015
Citations: 27	License type: CC BY 4.0

Affiliation: Kōchi University

Abstract

Background: We have developed a new radiosensitization treatment called Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Using KORTUC II, we performed breast-conserving treatment (BCT) without any surgical procedure for elderly patients with breast cancer in stages I/II or patients refusing surgery. Since surgery was not performed, histological confirmation of the primary tumor region following KORTUC II treatment was not possible. Therefore, to precisely evaluate the response to this new therapy, a detailed diagnostic procedure is needed. The goal of this study was to evaluate the therapeutic response to KORTUC II treatment in patients with stage I/II breast cancer using annual breast contrast-enhanced (CE) magnetic resonance imaging (MRI). Methods: Twenty-one patients with stage I/II breast cancer who were elderly and/or refused surgery were enrolled in this study. All patients underwent MRI prior to and at 3 to 6 months after KORTUC II, and then approximately biannually thereafter. Findings from MRI were compared with those from other diagnostic modalities performed during the same time period. Results: KORTUC II was well tolerated, with minimal adverse effects. All of 21 patients showed a clinically complete response (cCR) on CE MRI. The mean period taken to confirm cCR on the breast CE MRI was approximately 14 months. The mean follow-up period for the patients was 61.9 months at the end of October 2014. Conclusions: The therapeutic effect of BCT using KORTUC II without surgery could be evaluated by biannual CE MRI evaluations. Approximately 14 months were required to achieve cCR in response to this therapy.

Highlights

Using a current linear accelerator, our intent was to inactivate peroxidase/catalase in tumor tissueUsing by the application of hydrogen is degraded to produceinoxygen, a current linear accelerator, ourperoxide, intent waswhich to inactivate peroxidase/catalase tumor tissue re-oxygenating theoftumor tissue [1,2,3]
In seven of the 21 patients examined in the study, (KORTUC-breast-conserving treatment (BCT))
BCT generally includes surgery, these results suggest that non-surgical BCT consisting of radiation therapy alone can be performed by using this new KORTUC II radiosensitization treatment

Summary

Introduction

Using a current linear accelerator, our intent was to inactivate peroxidase/catalase in tumor tissueUsing by the application of hydrogen is degraded to produceinoxygen, a current linear accelerator, ourperoxide, intent waswhich to inactivate peroxidase/catalase tumor tissue re-oxygenating theoftumor tissue [1,2,3]. In this way, we cantoconvert tumors from to by the application hydrogen peroxide, which is degraded produce oxygen, thusradioresistant re-oxygenating radiosensitive. The In basis this we strategy, we hadtumors previously a new enzyme-targeting the tumor tissueOn [1,2,3]. Carcinomas, the basis of this strategy, wenamed had previously developed a new enzyme-targeting radiosensitization Type I

Objectives

Methods

Results

Discussion

Conclusion